Florox 100ml
DESCRIPTION
Florox is one of the most affordable professional antibacterial preparations based on florfenicol on the market of the Russian Federation and the CIS countries, with prolonged action against respiratory diseases of calves and piglets. In appearance it is a colorless liquid.
ADVANTAGES
Florfenicol is specially formulated for veterinary use
Reduction of losses of young animals and preservation of weight gain due to the rapid action of the drug
Increased bioavailability
COMPOSITION
1 ml contains 300 mg of florfenicol and auxiliary components as an active ingredient.
PHARMACOLOGICAL PROPERTIES
Florfenicol, which is part of the drug, is a thiamphenicol derivative, in the molecule of which the hydroxyl group is replaced by a fluorine atom. It has a bacteriostatic effect, binding in the protoplasm of a bacterial cell with the ribosomal subunit 70S, blocking the enzyme peptidyl transferase, which leads to inhibition of protein synthesis in sensitive microorganisms at the ribosome level. Active against bacteria that produce acetyltransferase and are resistant to chloramphenicol. Florfenicol has a broad spectrum of action against Staphylococcus spp., Streptococcus spp., Escherichia coli, Actinobacillus pleuropneumoniae, Pasteurella spp., Bordetella bronchiseptica, Haemophilus spp., Fusobacterium necrophorium and M. hyeneumoniae, M. hyneopneumoniae, Klebciella pneumopneumoniae, and Klebciella pneumopneumoniae. After parenteral administration of the drug, florfenicol is rapidly absorbed and penetrates into most organs and tissues, reaching maximum serum concentrations after 30-90 minutes, and remains in the body at a therapeutic concentration for at least 48 hours. The antibiotic is excreted from the body in unchanged form and in the form of metabolites, mainly with urine and, to a lesser extent, with feces.
PURPOSE
Florox is prescribed to pigs and cattle for the treatment of diseases of bacterial etiology, the causative agents of which are sensitive to florfenicol.
Swine: Respiratory diseases including pleuropneumoniae caused by Actinobacillus pleuropneumoniae and / or Haemophilus parasuis, Pasteurella multocida, M. hyopneumoniae, M. hyorhinis and atrophic rhinitis.
Cattle: respiratory diseases caused by Pasteurella multicida, Klebciella pneumoniae, Streptococcus pneumoniae, Haemophilus somnus, necrobacillosis, infectious keratoconjunctivitis caused by Moraxella bovis.
DOSAGE AND APPLICATION
In pigs, the drug is injected intramuscularly into the neck at a dose of 1 ml per 20 kg of animal weight (15 mg / kg florfenicol) twice with an interval of 48 hours. In cattle, the drug is administered intramuscularly twice with an interval of 48 hours at a dose of 1 ml per 15 kg of animal weight (20 mg / kg of florfenicol) or subcutaneously once in a dose of 2 ml per 15 kg of animal weight (40 mg / kg of florfenicol).
LIMITATIONS
Slaughter of pigs for meat is allowed no earlier than 14 days, cattle no earlier than 34 days after the last intramuscular injection and 42 days after the last subcutaneous injection of Florox. The meat of animals that were forcedly killed before the expiration of the specified period can be used as feed for fur animals.
SHELF LIFE AND STORAGE
Store the medicinal product in the manufacturer's closed packaging, separately from food and feed, in a place protected from direct sunlight, at a temperature of 5 В° C to 25 В° C. The shelf life of the drug, subject to the storage conditions in the manufacturer's closed packaging, is 2 years from the date of production, after the first opening of the bottle - no more than 30 days.
PACKAGING
Florox is produced packaged in 100 ml bottles in glass bottles of appropriate capacity, hermetically sealed with rubber stoppers, reinforced with aluminum caps with clips for first opening control. Each consumer package is supplied with instructions for using the drug.
Specifications
KolVUP
50
Manufacturer
Nita-Farm
Temperature regime
from +5 to +25
Teaser
for the treatment of respiratory diseases, as well as for necrobacillosis and infectious keratoconjunctivitis; pigs with respiratory diseases, including pleuropneumonia, as well as atrophic rhinitis